Azacitidine Injection, Powder, Lyophilized, For Solution
Product Images NDC 16729-306

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Azacitidine (NDC 16729-306). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Accord Healthcare Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (100 mg azacitidine-for-inj-carton)

This is a description for an Azacitidine injection in a single-dose vial. The product is a lyophilized powder that must be diluted and used for subcutaneous and intravenous use only. It contains azcitidine and mannitol, and is a cytotoxic agent. The usual dosage and administration information can be found in the prescribing information. The vial should be stored at a controlled room temperature and should be kept out of reach of children. The product is manufactured by Accord Healthcare and Intas Pharmaceuticals Limited. The NDC number for the product is 16729-306-10. The vial has an unvarnished area for pasting.*

FDA Label Image

Principal Display Panel (100 mg azacitidine-for-inj-label)

Azacitidine is a drug that is available in a single-dose vial for subcutaneous and intravenous use. The usual dosage and instructions are prescribed by a healthcare professional. It contains azacitidine and mareto as its main ingredients. This product is manufactured by Natas Pharmaceuticals Limited and it is cautioned to be kept out of reach of children. The label also contains important information like manufacturing date, manufacturing company address, and license number.*

FDA Label Image

Kaplan-meier Curve Of Time To Death From Any Cause: (intent-to-treat Population) (Azacitidine For Inj Plot)

This appears to be a graph or table showing the survival rates of two groups (AZA and CCR) over a period of time (measured in months). The results of a statistical test are also shown, with a p-value of 0.0001 indicating that there is a significant difference in survival rates between the two groups. The hazard ratio (HR) is listed as 0.58 with a 95% confidence interval of 0.43-0.77. The number of deaths is also provided for each group (82 for AZA and 113 for CCR).*

FDA Label Image

Azacitidine For Inj Structure

This text represents a chemical formula showing the structure of a molecule with three atoms. It is not possible to determine the specific compound it represents without additional information.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.